VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO 2019 | Dr Camidge on novel NSCLC agents: we want to see the duration of benefit

Ross Camidge, MD, PhD, University of Colorado, Denver, CO, gives his thoughts on the new data in lung cancer – highlighting the need to see a duration of benefit. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter